Close X
Attorney Spotlight

Find out which two countries Cheryl Palmeri gets the most questions about related to International Trade in today's market? Find out more>


Close X


Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Danielle Sloane and Courtney Ginn Discuss FDA Enforcement Related to Labs Marketing Directly to Consumers

G2 Compliance Advisor


March 23, 2016

Bass, Berry & Sims attorneys Danielle Sloane and Courtney Ginn authored an article outlining the new FDA enforcement actions against laboratory developed tests (LDTs) that are marketed and sold directly to consumers. Although LDTs have historically been exempt from FDA regulation, as technology and testing options have developed and become more sophisticated, more regulation may be on the horizon for these types of tests. As Danielle and Courtney point out in the article, "[i]In late 2015 and early 2016, the FDA issued five warning letters to companies engaging in DTC [direct to consumers] marketing of LDTs. In several of these letters, it appears the FDA may be going beyond situations in which the consumer can order the test directly to also regulate situations in which the practitioner signing the order is affiliated with the laboratory."

The full article, "Marketing of Laboratory Tests to Consumers: Is a Practitioner Order Enough to Avoid FDA Enforcement," was published in the March 2016 issue of G2 Compliance Advisor and is available online (subscription required).

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.